Abstract
The term “compensated advanced chronic liver disease” (cACLD) was introduced at Baveno VI to denominate patients with chronic liver disease at risk of developing clinically significant portal hypertension based on liver stiffness values. The concept has been consolidated and adopted in many publications regarding portal hypertension complications of chronic liver disease. At Baveno VII, we have proposed a change in the clinical substrate that provides support to the evidence for the concept and the liver stiffness cutoffs (<10 kPa and >15 kPa) used to identify it. A shift has been performed linking the cACLD concept to the risk of developing clinical events rather than the risk of presenting with severe fibrosis/cirrhosis in the liver biopsy. Based on that, the three subgroups of patients determined by the liver stiffness cutoffs of cACLD identify patients with a progressively increasing risk of liver-related events during follow-up.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.
Davison B, Harrison S, Cotter G, Alkhouri N, Sanyal A, Edwards C, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322–32.
Wong VWS, Irles M, Wong GLH, Shili S, Chan AWH, Merrouche W, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 2019;68:2057–64.
Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, et al. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. Liver Int. 2020;40:1151–8.
Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74:1109–16.
Ji Y, Li J, He Q, Zhou L, Chen J. Baveno VI elastography criteria for ruling in cACLD works well in MAFLD patients. J Hepatol. 2021;75:1243–5.
Zhou Y, Gao F, Liu W, Wong GL, Mahadeva S, Raihan Nik Mustapha N, et al. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:470–80.
Rivera J, Calleja J, Aller R, Gonzalo-Benito H, Arias-Loste M, Ireuzubieta P, et al. Prevalence estimation of significant fibrosis due to non-alcoholic steatohepatitis combining transient elastography and histology. J Hepatol. 2021;75:S255.
Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2021;116:723–32.
Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.
Fung J, Lai CL, Seto WK, Wong DKH, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat. 2011;18:738–44.
Vergniol J, Foucher J, Terrebonne E, Bernard P, Le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970–1979.e3.
Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.
Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, Chazouillères O, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198–208.
Klibansky DA, Mehta SH, Curry M, Nasser I, Challies T, Afdhal NH. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat. 2012;19:e184–93.
Pang JXQ, Zimmer S, Niu S, Crotty P, Tracey J, Pradhan F, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One. 2014;22:e95776.
Corpechot C, Gaouar F, Naggar AEI, Kemgang A, Wendum D, Poupon R, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014;146:970–979.e6.
Tatsumi A, Maekawa S, Sato M, Komatsu N, Miura M, Amemiya F, et al. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatol Res. 2015;45:523–32.
Shili-Masmoudi S, Wong GLH, Hiriart JB, Liu K, Chermak F, Shu SST, et al. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int. 2020;40:581–9.
Rasmussen DN, Thiele M, Johansen S, Kjærgaard M, Lindvig KP, Israelsen M, et al. Prognostic performance of seven biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol. 2021;75(5):1017–25. https://doi.org/10.1016/j.jhep.2021.05.037.
Grgurevic I, Salkic N, Mustapic S, Bokun T, Podrug K, Marusic S, et al. Liver and nonliver-related outcomes at 2 years are not influenced by the results of the FIB-4 test and liver Elastography in a real-life cohort of patients with type 2 diabetes. Can J Gastroenterol Hepatol. 2021;2021:5582813.
Petta S, Wai-Sun Wong V, Bugianesi E, Fracanzani AL, Cammà C, Hiriart JB, et al. Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2019;114:916–28.
Dietrich C, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound Elastography, update 2017 (long version). Ultraschall Med. 2017;38:e16–47.
Ferraioli G, Wong V, Castera L, Berzigotti A, Sporea I, Dietrich C, et al. Liver ultrasound Elastography: an update to the World Federation for Ultrasound in medicine and biology guidelines and recommendations. Ultrasound Med Biol. 2018;44:2419–40.
Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the Society of Radiologists in ultrasound liver elastography consensus statement. Radiology. 2020;296:263–74.
Palmeri M, Nightingale K, Fielding S, Rouze N, Deng Y, Lynch T, et al. RSNA QIBA ultrasound shear wave speed phase II phantom study in viscoelastic media. IEEE Int Ultrason Symp. 2015;2015:1–4.
Cassinotto C, Lapuyade B, Guiu B, Marraud des Grottes H, Piron L, Merrouche W, et al. Agreement between 2-dimensional shear wave and transient elastography values for diagnosis of advanced chronic liver disease. Clin Gastroenterol Hepatol. 2020;18:2971–2979.e3.
European Association for the Study of the Liver. EASL Clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol. 2021;75:659–89.
Singh S, Venkatesh S, Wang Z, Miller F, Motosugi U, Low R, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13:440–451.e6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this paper
Cite this paper
Pons, M., Barreira, A., Genescà, J. (2022). Compensated Advanced Chronic Liver Disease (cACLD). In: de Franchis, R. (eds) Portal Hypertension VII. Springer, Cham. https://doi.org/10.1007/978-3-031-08552-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-031-08552-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-08551-2
Online ISBN: 978-3-031-08552-9
eBook Packages: MedicineMedicine (R0)